Prot #CAB-101: A Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-Dominant Pemphigus Vulgaris

Project: Research project

Project Details

StatusActive
Effective start/end date8/25/21 → 8/25/27

Funding

  • Novella Clinical, LLC ((OE) Prot #CAB-101 AMD 3 // (OE) Prot #CAB-101 AMD 3)
  • Cabaletta Bio, Inc. ((OE) Prot #CAB-101 AMD 3 // (OE) Prot #CAB-101 AMD 3)